Acadia Pharmaceuticals

Acadia Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing small molecule drugs targeting unmet medical needs in central nervous system disorders. Its primary product, NUPLAZID (pimavanserin), treats hallucinations and delusions associated with Parkinson's disease psychosis.

Kevin R. Oliver

Senior Vice President and Chief Business Officer

Elizabeth H.Z. Thompson

Executive Vice President, Head of Research and Development

1 past transactions

CerSci Therapeutics

Acquisition in 2020

CerSci Therapeutics Inc. is a Dallas, Texas-based biotechnology company focused on developing non-opioid alternatives for the treatment of acute post-operative and chronic neuropathic pain, including pain associated with diabetes and chemotherapy. Founded in 2015, the company is advancing its lead drug candidate, CT-044, which has received approval from the United States Food and Drug Administration to proceed with Phase I clinical trials. CT-044 is a small molecule designed to decompose radical species such as peroxynitrite and hydrogen peroxide, and it is intended to address both acute and chronic pain conditions. As of August 2020, CerSci Therapeutics operates as a subsidiary of ACADIA Pharmaceuticals Inc.

Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.